Li Si-Wei, Feng Xue, Xu Hao, Chen Ke-Ji
Cardiovascular Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Xiyuan Hospital, Postdoctoral Research Station of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Chin J Integr Med. 2018 Feb;24(2):103-108. doi: 10.1007/s11655-017-2419-7. Epub 2017 Oct 25.
To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer.
Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time (ACT), clot rate (CR) and platelet function (PF) by Sonoclot coagulation and platelet function analyzer instrument.
For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear (or log linear) relationship between ACT, CR, PF value and drug concentration (P<0.01). Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride (P<0.01). Under the same ACT values, the puerarin corresponding CR values (CR = e, P<2.2e-16) were always higher than the corresponding values (CR = e, P-value<2.2e-16) of heparin sodium. For high concentrations of puerarin (e.g. 3.8 mg/600 μL) and tirofiban hydrochloride (e.g. 0.8 μg/600 μL), PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance.
Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.
通过Sonoclot凝血和血小板功能分析仪检测不同浓度的葛根素、肝素钠和盐酸替罗非班对健康志愿者血液样本的抗凝和抗血小板作用。
从20名健康志愿者中采集外周血样本，随后加入不同浓度的葛根素、肝素钠和盐酸替罗非班。使用Sonoclot凝血和血小板功能分析仪检测样本的活化凝血时间（ACT）、凝血率（CR）和血小板功能（PF）。
对于葛根素和肝素钠，随着药物浓度增加，ACT值逐渐升高,CR和PF值逐渐降低。ACT、CR、PF值与药物浓度之间存在线性（或对数线性）关系（P<0.01）。对应每个值，得到一个回归方程。对于盐酸替罗非班，ACT和CR值无显著变化，而PF值随浓度增加逐渐降低。PF值与盐酸替罗非班浓度之间也存在线性关系（P<0.01）。在相同ACT值下，葛根素对应的CR值（CR = e，P<2.2e-16）始终高于肝素钠的对应值（CR = e，P值<2.2e-16）。对于高浓度的葛根素（例如3.8 mg/600 μL）和盐酸替罗非班（例如0.8 μg/600 μL），PF值无显著差异。然而，高浓度葛根素的PF值方差较大。
葛根素与肝素钠具有相似的抗凝和抗血小板作用，并且在本实验浓度范围内获得相同抗凝效果时，其出血风险可能低于肝素钠。此外，对于高浓度，葛根素与盐酸替罗非班具有相同的抗血小板功能，但个体变异性较大。
